Concepedia

Anna Perols

AP

13

Publications

451

Citations

13

H-Index

2011

Active since

Affiliations

KTH Royal Institute of Technology(Current)

Uppsala University

AlbaNova

Uppsala University Hospital

University of Turku

Anna Perols is an author at KTH Royal Institute of Technology specializing in medicine, molecular biology, and drug discovery.

Top concepts

Publications per year

2011–2018

13

Publications

13

Influence of Macrocyclic Chelators on the Targeting Properties of 68Ga-Labeled Synthetic Affibody Molecules: Comparison with 111In-Labeled Counterparts

Joanna Strand, Hadis Honarvar, Anna Perols et al. · PLoS ONE · 2013 · 60 citations · Full text

Feasibility of Affibody-Based Bioorthogonal Chemistry–Mediated Radionuclide Pretargeting

Mohamed Altai, Anna Perols, Maria Tsourma et al. · Journal of Nuclear Medicine · 2015 · 59 citations · Full text

Comparative Evaluation of Anti-HER2 Affibody Molecules Labeled with <sup>64</sup>Cu Using NOTA and NODAGA

Vladimir Tolmachev, Cheng‐Bin Yim, Johan Rajander et al. · Contrast Media & Molecular Imaging · 2017 · 56 citations · Full text

Comparative evaluation of synthetic anti-HER2 Affibody molecules site-specifically labelled with 111In using N-terminal DOTA, NOTA and NODAGA chelators in mice bearing prostate cancer xenografts

Jennie Malmberg, Anna Perols, Zohreh Varasteh et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2011 · 46 citations

, , +8

Influence of DOTA Chelator Position on Biodistribution and Targeting Properties of <sup>111</sup>In-Labeled Synthetic Anti-HER2 Affibody Molecules

Anna Perols, Hadis Honarvar, Joanna Strand et al. · Bioconjugate Chemistry · 2012 · 45 citations

, , +19

Rows per page

1–5 of 13